Related Experiment Video
Updated: Jul 6, 2025
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Retinitis pigmentosa GTPase regulator-related retinopathy and gene therapy
Nida Wongchaisuwat1,2, Alessia Amato2, Andrew E Lamborn2
1Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Insights
Retinitis pigmentosa GTPase regulator (RPGR)-related retinopathy is an X-linked inherited condition causing progressive vision loss. Gene therapy clinical trials are underway to slow disease progression and potentially restore vision.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- RPGR-related retinopathy is a severe, X-linked inherited retinal dystrophy.
- It leads to progressive vision loss from childhood, causing severe impairment by age 40.
- Currently, no effective treatments exist for this condition.
Purpose of the Study:
- To review the molecular biology of RPGR-related retinopathy.
- To describe the clinical manifestations of the disease.
- To summarize recent advancements in gene therapy clinical trials.
Main Methods:
- Literature review of molecular biology.
- Analysis of clinical data on disease presentation.
- Overview of ongoing gene therapy clinical trials.
Main Results:
- RPGR gene mutations are the cause of this specific retinopathy.
- The disease follows a predictable pattern of visual field constriction and acuity loss.
- Gene augmentation therapy trials show promise in early stages.
Conclusions:
- RPGR-related retinopathy is a significant cause of inherited blindness.
- Gene therapy offers a potential therapeutic strategy.
- Further research and clinical trials are crucial for effective treatment development.
Abstract:
Retinitis pigmentosa GTPase regulator (RPGR)-related retinopathy is a retinal dystrophy inherited in a X-linked recessive manner that typically causes progressive visual loss starting in childhood with severe visual impairment by the fourth decade of life. It manifests as an early onset and severe form of retinitis pigmentosa. There are currently no effective treatments for RPGR-related retinopathy; however, there are multiple clinical trials in progress exploring gene augmentation therapy aimed at slowing down or halting the progression of disease and possibly restoring visual function. This review focuses on the molecular biology, clinical manifestations, and the recent progress of gene therapy clinical trials.
